Rubicon Research IPO
- Issue price
- ₹485
- Listing price
- ₹620
- +27.84%
- Current price
- ₹1,679.3
- +246.25%
- Subscribed
- —
- Issue size
- ₹1,378 Cr
- Listed on
- 16 Oct 2025
IPO timeline
- Opens9 OctThu
- Closes13 OctMon
- Allotment14 OctTue
- Refunds15 OctWed
- Demat credit15 FebSun
- Listing16 OctThu
Issue details
- Price band
- ₹461 – ₹485 per share
- Issue size
- ₹1,378 Cr
- Fresh issue
- ₹500.18 Cr · 1.03 Cr shares
- Offer for sale
- ₹877.82 Cr
- Issue type
- Fresh capital cum OFS
- Face value
- ₹1 per share
- Lot size
- 30 shares
- Minimum investment
- ₹14,550
- Listing on
- BSE, NSE
- Exchange code
- RUBICON.BO
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 30 | ₹14,550 |
| Retail (Max) | 13 | 390 | ₹1,89,150 |
| S-HNI (Min) | 14 | 420 | ₹2,03,700 |
| B-HNI (Min) | 69 | 2,070 | ₹10,03,950 |
Reservation
- QIB
- 2,12,74,485 shares (75.00% of the Offer)
- NII
- 42,54,896 shares (15.00% of the Offer)
- Retail
- 28,36,597 shares (10.00% of the Offer)
- Employee
- 39,863 shares (0.14% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 14 Oct 2025
- Refunds initiated
- 15 Oct 2025
- Shares credited to demat
- 15 Feb 2026
- Listing
- 16 Oct 2025
Grey market premium (GMP)
- Current GMP
- ₹68
- +14.00%
- Estimated listing price
- ₹553
- Issue price ₹485
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
Subscription figures are not available for this issue.
Financials
- P/E (pre-issue)
- 43.25
- P/E (post-issue)
- 46.13
- EPS (₹)
- 10.51
- RoCE
- 26.45%
- RoNW
- 29.02%
- PAT Margin
- 10.37%
Pre-issue P/E uses the shares outstanding before the IPO; post-issue P/E includes the new shares. Calculated by Be IPO Ready at the issue price on profit for the period ended 30 Jun 2025, annualised.
| Period ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 356.95 | 1,296.22 | 872.39 |
| OPM % | 19.9 | 18.1 | |
| EBITDA | 79.74 | 267.89 | 173.09 |
| Net Profit | 43.30 | 134.36 | 91.01 |
| Debt | 495.78 | 393.17 | 396.41 |
| Assets | 1,647.60 | 1,451.43 | 1,109.49 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Rubicon Research This IPO | ₹1,378 Cr | 46.13 | 29.02% | 10.37% | 109.32x | +27.84% |
| Paras Healthcare Mainboard · listed 28 Oct 2026 | ₹1,450 Cr | 37.72 | 11.83% | 10.38% | 2.23x | +3.90% |
| Entero Healthcare Solutions Mainboard · listed 16 Feb 2024 | ₹1,600 Cr | 129.75 | -1.86% | 4.69% | 1.56x | -2.33% |
| Medi Assist Healthcare Services Mainboard · listed 23 Jan 2024 | ₹1,171.58 Cr | 31.8 | 19.63% | 14.51% | 16.25x | +10.05% |
| Symbiotec Pharmalab Mainboard · listed 1 Sep 2026 | ₹1,757 Cr | 56.81 | 9.48% | 12.60% | 71.26x | 0.00% |
| Indegene Mainboard · listed 13 May 2024 | ₹1,841.76 Cr | 33.53 | 18.23% | 12.62% | 70.3x | +44.91% |
| Akums Drugs & Pharmaceuticals Mainboard · listed 6 Aug 2024 | ₹1,856.74 Cr | 13580 | -0.57% | 0.02% | 63.44x | +6.77% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Rubicon Research plans to use the money raised, as stated in the offer document.
- Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company₹310 Cr
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes₹161.27 Cr
- Issue Expenses₹79.12 Cr
About Rubicon Research
Rubicon Research is a pharmaceutical company focused on developing and manufacturing high-quality generic medicines, with a strong emphasis on complex formulations and drug delivery systems. The company was established with the vision of catering to regulated markets such as the United States and Europe, and over the years, it has built capabilities in research, formulation development, and manufacturing. Rubicon operates through a vertically integrated model, supported by its research and development centres and manufacturing facilities that comply with global regulatory standards. The company offers a range of pharmaceutical products, including oral solids, injectables, and other specialty formulations, targeting therapeutic segments such as central nervous system (CNS), cardiovascular, and oncology. Rubicon Research is promoted by experienced professionals with deep industry expertise, who have played a key role in shaping its growth strategy and global presence. Its business model is driven by product development partnerships, contract manufacturing, and direct sales in key markets, enabling it to generate revenue through both proprietary products and collaborations with global pharmaceutical companies.
Promoters and shareholding
General Atlantic Singapore RR Pte.Ltd, Parag Suganchand Sancheti, Pratibha Pilgaonkar, Sudhir Dhirendra Pilgaonkar, Sumant Sudhir Pilgaonkar, Surabhi Parag Sancheti
- Shares outstanding, pre-issue
- 15,44,37,251
- Shares outstanding, post-issue
- 16,47,50,309
Registrar, lead managers and documents
Company contact
MedOne House, B-75, Road No.33, Wagle Estate, Thane, Maharashtra, 400604
022 61414000
investors@rubicon.co.inRubicon Research IPO: common questions
1.When does the Rubicon Research IPO open and close?
The Rubicon Research IPO opens on 9 Oct 2025 and closes on 13 Oct 2025.
2.What is the price band of the Rubicon Research IPO?
The price band is ₹461 – ₹485 per share, with a lot size of 30 shares and a minimum investment of ₹14,550.
3.What is the size of the Rubicon Research IPO?
The issue size is ₹1,378 Cr (Fresh capital cum OFS).
4.What is the GMP of the Rubicon Research IPO?
The last reported grey market premium is ₹68 per share as of 06 Oct 2025, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Rubicon Research IPO allotment?
The basis of allotment is expected on 14 Oct 2025. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Rubicon Research IPO list?
The shares listed on 16 Oct 2025 on BSE, NSE.
7.Who is the lead manager of the Rubicon Research IPO?
The book running lead managers are JM Financial Ltd., SBI Capital Markets Ltd., Axis Capital, IIFL Capital Services Limited, and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Rubicon Research IPO be used for?
As stated in the offer document, the proceeds are for: Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company; Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes; Issue Expenses.
9.How can my company launch an IPO like Rubicon Research?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393